TW201144282A - Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds - Google Patents

Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds Download PDF

Info

Publication number
TW201144282A
TW201144282A TW099142648A TW99142648A TW201144282A TW 201144282 A TW201144282 A TW 201144282A TW 099142648 A TW099142648 A TW 099142648A TW 99142648 A TW99142648 A TW 99142648A TW 201144282 A TW201144282 A TW 201144282A
Authority
TW
Taiwan
Prior art keywords
formula
solvent
compound
metal catalyst
hydrogen
Prior art date
Application number
TW099142648A
Other languages
English (en)
Inventor
Hossein Razavi
Jonathan T Reeves
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW201144282A publication Critical patent/TW201144282A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

201144282 六、發明說明： 【發明所屬之技術領域】 本發明係關於一種製備式（I)化合物之新穎的方法：
/、、0 其作係用於製備經取代吲唑及氮雜吲唑化合物之中間物。 本申請案主張於2009年12月8曰申請之美國臨時申請案 第61/267,538號之權益。 【先前技術】 式II之經取代吲唑及氮雜吲唑化合物已描述為CCR1之抑 制劑。該等化合物之實例揭示於WO 2009/1 34666及WO 2010/036632中。該等化合物係用於治療經由CCR1活性調 節或維持之各種疾病及失調症，包括自身免疫疾病，例如 類風濕性關節炎及多發性硬化。
Ο R. R
II(X=C 或 N) 合成此等化合物之關鍵步驟係形成醯胺鍵。已揭示若干 方法以完成此。例如，參考文獻WO 2010/036632中所揭 示，其中所描述之式II化合物可藉由使（V)及式（VI)胺反應 151427.doc 201144282 而製備’如下圖所示：
V VI 上述合成經取代吲唑及氮雜吲唑化合物之中間物實質上 係胺中間物V卜已知的中間物VI之合成包括使下述氰基化 合物轉化為對應的胺並通過2個步驟方法完成，該2個步驟 方法包括1)減少硼氫化鈉/三氟乙酸/溴化鋅並原位進行丁 氧基幾基化作用，
NHPG 、'0 —s'丨 R 々ο 气 1 · NaBH4 2. t護基 of。 及2)利用含於異丙醇之濃鹽酸脫去叔丁氧基羰基之保護。 NHPG Η 酸 nh2 °1"° 〇t〇 【發明内容】 本發明之合成方法較之已知方法具有以下優點： 1) 需要1個步驟而非兩個步驟，因此減少勞動力成本及週 期時間； 2) 由於無需Boe gf、》臭化鋅、仏卵4、或tfa減少成 151427.doc 201144282 本； 3) 由於其可在使用Na BH4/TFA時避免㈣形成之可能性， 故提高安全性； 4) 可於工業、商業規模下使用氫化作用。 t本發月之目的係、提供—種製備式⑴之胺中間物具有 上述優點之常規方法。 【實施方式】 於最廣泛通用之實施例中，提供_種製備離子鹽形式之 式（I)化合物之方法： nh2
其包括： i)於0至loot，較佳25。(：下，利用金屬觸媒，較佳以以或 Νι為主之觸媒，更佳鈀覆碳，最佳含水之1〇% ，尤佳 10% Pd/50。/。水之觸媒，以氫氣，較佳壓力為15至1〇〇〇 (較佳100至200psi)之氫氣，歷時2至2〇小時，最佳7小時， 將式（II)化合物氫化，並濾去該觸媒，然後以酸溶液或氣 體，較佳以濃鹽酸水溶液處理，該反應係在選自醇溶劑、 酯溶劑、酸之水溶液、醚及甲苯或其他芳香烴溶劑之溶劑 (較佳為曱醇、乙醇、異丙醇或乙酸，更佳為甲醇）中進 行’以提供式（I)化合物： 151427.doc 201144282
觸媒/¾
其中R係氫或C1-10烷基，較佳為C1_5烷基，更佳為甲基β 於本發明之另一實施例中提供一種根據上述實施例製備 式⑴化合物之方法，且其中 式（Π)之腈係在4之位置：
(II)， 且所得之胺基係在式（I)之4位置 ΝΗ.
本說明書中所使用之所有術語（除另外說明之外）應理解 為相關技術中所知之其等的普通含義β 術語「院基」係指包含丨至10個碳原子之飽和脂肪族基 團。「烧基」同時指支鏈或無支鏈烷基。 本發明之該等化合物僅係熟習此項技術者所瞭解之視為 「化學穩定」之彼等。 闡述以下實例以使此發明得以更充分為人理解。此等實 151427.doc •6- 201144282 例係出於闡明此發明較佳實施例之目的，而並非意欲以任 何方式限制本發明範圍。 合成實例
以 2-(曱基橫 gf 基）-4·氰基°比〇定（8.00 g，43.9 mmol)、1〇 重量 ％ Pd/C(50%水）(800 mg，0.377 mmol)及 MeOH(48 ml) 注滿一氫化管。於25°C 100 psi氫氣下歷時7小時使該混合 物氫化。過濾該反應混合物以移除該觸媒，用Me〇H沖洗 並濃縮該濾液至體積為24 m卜添加異丙醇（48 ml)，然後 濃鹽酸（4.03 ml，48.3 mmlo ’ 1.1 eq)。攪拌所得漿歷時18 小時，過濾’並以異丙醇沖洗所得固體並於真空下乾燥。 獲得呈固體（8.10 g，產率82%)之產物2-(甲基磺醯基）吡啶_ 4-基）曱胺鹽酸鹽，其經HPLC分析不含脫磺醯基雜質，且 具有46 ppm殘餘Pd含量。 151427.doc

Claims (1)

  1. 201144282 七、申請專利範圍： 1· 一種製備離子鹽形式之式（I)化合物之方法：
    其包括： i) 利用金屬觸媒於0至100°C下以氫氣使式（II)化合物氫化 2至20小時，及 ii) 濾去該觸媒然後以酸性溶液或氣體處理，其中該反應 係在選自醇溶劑、酯溶劑、酸之水溶液、醚及甲醇或其 他芳香烴溶劑之溶劑中進行，以提供式（I)化合物：
    其中R係氫或C1-10烷基。 2.如請求項1之方法，其中： 該金屬觸媒係以Pd或Ni為主之觸媒； 該氫氣係在15至lOOOpsi之壓力下； 時間為7小時； 溫度為25°C ; 該酸係濃鹽酸水溶液； 151427.doc 201144282 該溶劑係選自甲醇、乙醇、異丙醇及乙酸； 該離子鹽係氫氣化物。 3. 如請求項1或2之方法，其中： 該金屬觸媒為鈀覆碳； 該氫氣係在1〇〇至200psi之壓力下； 該溶劑係曱醇。 4. 如請求項1或2之方法，其中： 該金屬觸媒為10%鈀覆碳，其含水； 5. 如請求項1或2之方法，其中： 該金屬觸媒10%鈀覆碳，其含5〇%水； 6. 如請求項1或2之方法，其中： 式（Π)之腈係在4之位置：
    且所得之胺基係在式（I)之4位置
    7. 如請求項1或2之方法，其中尺係^乃烷基。 8. 如睛求項1或2之方法，其中r係甲基。 151427.doc 201144282 四、指定代表圖： (一) 本案指定代表圖為：（無） (二) 本代表圖之元件符號簡單說明： 五、本案若有化學式時，請揭示最能顯示發明特徵的化學式：
    (I) 151427.doc
TW099142648A 2009-12-08 2010-12-07 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds TW201144282A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08

Publications (1)

Publication Number Publication Date
TW201144282A true TW201144282A (en) 2011-12-16

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099142648A TW201144282A (en) 2009-12-08 2010-12-07 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Country Status (16)

Country Link
US (1) US20110137042A1 (zh)
EP (1) EP2509952A1 (zh)
JP (1) JP2013512954A (zh)
KR (1) KR20120101667A (zh)
CN (1) CN102596908A (zh)
AR (1) AR079324A1 (zh)
AU (1) AU2010328480A1 (zh)
BR (1) BR112012013582A2 (zh)
CA (1) CA2782384A1 (zh)
CL (1) CL2012001300A1 (zh)
EA (1) EA201200820A1 (zh)
IL (1) IL219274A0 (zh)
IN (1) IN2012DN05081A (zh)
MX (1) MX2012006524A (zh)
TW (1) TW201144282A (zh)
WO (1) WO2011071730A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722923C (en) 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
CN102227425A (zh) 2008-09-26 2011-10-26 贝林格尔·英格海姆国际有限公司 作为ccr1受体拮抗剂的氮杂吲唑化合物
EP2491028B1 (en) 2009-10-21 2013-12-11 Boehringer Ingelheim International GmbH Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしての複素環化合物
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
WO2012087782A1 (en) 2010-12-23 2012-06-28 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as ccr1 receptor antagonists

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
BR9305569A (pt) * 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0657450B1 (en) * 1993-06-25 1998-09-09 KumaiI Chemical Industry Co., Ltd. Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof
AU699281B2 (en) * 1994-12-06 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
EA200000385A1 (ru) * 1997-11-04 2000-10-30 Пфайзер Продактс Инк. Терапевтически активные соединения на основе индазольной биоизостерической замены катехина в ингибиторах фосфодиэстеразы типа vi (pde4)
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
WO2000076971A2 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Serine protease inhibitors
AU5895500A (en) * 1999-06-29 2001-01-31 Cor Therapeutics, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
ES2338539T3 (es) * 2001-11-01 2010-05-10 Icagen, Inc. Pirazolamidas para uso en el tratamiento del dolor.
US7429609B2 (en) * 2002-05-31 2008-09-30 Eisai R & D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
NZ542671A (en) * 2003-03-12 2008-12-24 Celgene Corp 7-Amido-isoindolyl compounds and their pharmaceutical uses
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
WO2005016929A1 (en) * 2003-08-15 2005-02-24 Astrazeneca Ab Fused heterocylcles as inhibitors of glutamate racemase (muri)
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CA2599555A1 (en) * 2005-03-16 2006-09-21 Basf Aktiengesellschaft Biphenyl-n-(4-pyridyl) methylsufonamides
SI2444079T1 (sl) * 2005-05-17 2017-05-31 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje očesnih motenj
BRPI0615048A2 (pt) * 2005-09-01 2010-03-30 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
EP1940394A4 (en) * 2005-10-25 2009-07-08 Smithkline Beecham Corp CHEMICAL COMPOUNDS
BRPI0710110A2 (pt) * 2006-03-31 2011-08-02 Novartis Ag compostos orgánicos
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
CA2722923C (en) * 2008-04-29 2016-08-02 Boehringer Ingelheim International Gmbh Indazole compounds as ccr1 receptor antagonists
US8293917B2 (en) * 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
CN102227425A (zh) 2008-09-26 2011-10-26 贝林格尔·英格海姆国际有限公司 作为ccr1受体拮抗剂的氮杂吲唑化合物

Also Published As

Publication number Publication date
JP2013512954A (ja) 2013-04-18
AU2010328480A1 (en) 2012-05-17
MX2012006524A (es) 2012-07-17
BR112012013582A2 (pt) 2016-07-05
AR079324A1 (es) 2012-01-18
IN2012DN05081A (zh) 2015-10-09
CA2782384A1 (en) 2011-06-16
CN102596908A (zh) 2012-07-18
EP2509952A1 (en) 2012-10-17
WO2011071730A1 (en) 2011-06-16
EA201200820A1 (ru) 2013-01-30
KR20120101667A (ko) 2012-09-14
US20110137042A1 (en) 2011-06-09
IL219274A0 (en) 2012-06-28
CL2012001300A1 (es) 2012-09-07

Similar Documents

Publication Publication Date Title
TW201144282A (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
CN107406411B (zh) (r,s)-烟碱的制备方法
RU2719590C2 (ru) Способ получения антагонистов андрогенного рецептора и их промежуточных соединений
KR102230628B1 (ko) 보르티옥세틴 제조 방법
JP2011157370A5 (zh)
TW499409B (en) Method for preparing of L-phenylephrine hydrochloride
JP5503670B2 (ja) シナカルセト塩酸塩の製造方法
WO2022222914A1 (zh) 一种左旋烟碱的制备方法
WO2016055015A1 (zh) 一种不对称还原法制备西他列汀中间体的方法
CN113896728B (zh) 一种罗通定的合成制备方法
CN106674084B (zh) 一种2-异丙基氧基-5-甲基-4-(哌啶-4-基)苯胺二盐酸盐的制备方法
CN105348220A (zh) 一种氢溴酸沃替西汀的合成方法
JP4954201B2 (ja) ６，７，８−トリヒドロキシ−１−（ヒドロキシメチル）−３−オキソ−２−オキサ−４−アザビシクロ［３．３．１］ノナンの製造方法
US9745264B2 (en) Method for preparing silodosin and intermediate thereof
CN102321045B (zh) 一种制备高吗啉盐酸盐的方法
CN105254598A (zh) 一种合成3-四氢呋喃甲醇的方法
CN112552184A (zh) 一种含环丙基手性胺盐酸盐的合成方法
CN100448836C (zh) 一种抗艾滋病药物关键中间体的制备方法
CN110627768A (zh) 一种莫西沙星降解杂质j的制备方法
CN114507184B (zh) 1-甲基六氢氮杂卓-4-酮盐酸盐的合成方法及其应用
WO2011027319A1 (en) Process for the preparation of an intermediate for ramelteon
CN107805218B (zh) 一种制备4-Boc-氨基哌啶的方法
JP4769464B2 (ja) アルコール化合物の製造方法
JP2015227293A (ja) ２，３−ジハロゲノアニリンの製造方法
CN102020600A (zh) 一种吲哚-2-羧酸的合成方法